ClinicalTrials.gg
CompletedNCT01077960Updated Aug 7, 2013Results posted

Safety and Efficacy Study of Serostim® Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

A Phase 3 interventional study of Serostim in Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome, sponsored by EMD Serono. Completed at 26 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-07.

Sponsored by EMD Serono (part of Merck KGaA, Darmstadt, Germany) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
126
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

In Serono Study 24380, the antecedent protocol to Study 25373, patients were randomly assigned in a 3.0-to-1.0 ratio to Groups A and B. All patients in Group A received recombinant human growth hormone (Serostim®) 4 mg daily (the "induction" phase) for the first 12 weeks, and then were re-randomized to receive either placebo or Serostim 2 mg on alternate days (roughly equivalent to 1 mg daily) during Weeks 12-36 (the "maintenance" phase). All patients in Group B initially received placebo from baseline to Week 24, and then received Serostim® 4 mg daily from Weeks 24 to 36 (Grunfeld, 2007).

In the follow-up Study 25373, any subject who was enrolled in Serono Study 24380 and was assigned to Group A, who fully completed all study visits without a major protocol violation, was eligible to enroll to receive re-treatment with Serostim at a dose of 4 mg daily for 12 weeks. During study 25373, safety was monitored by recording of adverse events and measurement of urinalysis and laboratory blood tests to assess fasting glucose, fasting insulin, and routine biochemistry and hematology parameters. At Week 12 or at the time of study termination, subjects underwent re-assessment of body composition via anthropometry measurements and dual photon absorptiometry (DXA) scanning. In addition, at study termination, measurements of insulin-like growth factor I (IGF-I), insulin-like growth binding protein 3 (IGFBP-3), fasting lipid profile, and oral glucose tolerance testing were obtained.

02

Conditions studied

  • Human Immunodeficiency Virus-Associated Adipose Redistribution Syndrome

Keywords

  • Serostim
  • HARS
03

In context

Lead sponsor

EMD Serono is the lead sponsor of 91 studies on the registry; none are open to participants now.

First submitted after EMD Serono became part of Merck KGaA, Darmstadt, Germany.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Must meet all inclusion/exclusion criteria for Serono Study 25373, have participated in Serono Study 24380, must have been assigned to Group A, must have completed all treatments and procedures (including baseline, Week 12 and Week 36 Computerized Tomography (CT) and Dual-Energy X-ray Absorptiometry (DXA) Scans) and had no major protocol violation.
  • Must be taking antiretroviral medications that are approved or are available under a Treatment New Drug (IND). Subjects must also agree not to discontinue or to change their regimen for the duration of the study except as judged medically necessary.
  • Must be willing and able to comply with the protocol for the duration of the study.
  • Must have voluntarily provided written and a subject authorization under Health Insurance Portability and Accountability Act of 1996 (HIPAA), prior to any study-related procedure that is not part of normal medical care, and with the understanding that the subject may withdraw consent at any time without prejudice to future medical care.
  • If female, subjects must either:

    • Be post menopausal (=/>1 year) or surgically sterilized (i.e., have undergone tubal ligation or hysterectomy), or
    • Use a method for the duration of the study such as: hormonal contraceptive,intra uterine device,diaphragm with spermicide, or condom with spermicide, and
    • Must be neither pregnant nor breast feeding.
    • Confirmation that female subjects of are not pregnant must be established by a negative pregnancy test prior to initiating first treatment.

A pregnancy test is not required if the subject is post menopausal or surgically sterilized.

Exclusion criteria

Exclusion Criteria:

  • Have any condition, which interferes with or protocol compliance including, but not limited to, active substance abuse and/or dementia.
  • Have any active , except localized cutaneous Kaposi's sarcoma (fewer than 10 lesions, none of which are larger than 2 cm, and not on active therapy).
  • Have active central nervous system (CNS) process associated with neurological findings.
  • Have acute illness treated in an intensive care unit, e.g., due to complications following open heart or abdominal surgery, multiple accidental trauma, or acute respiratory failure.
  • Have any medical condition in view of which the study doctor and/or Serono Medical/Therapeutic Director feels that it would be in the best interest of the subject not to participate in the follow-up study.
  • Are unable to comply with the Concomitant Therapy restrictions as outlined in Section 5.5 and listed as follows:

    • Therapy for obesity including therapy with anorexigenic or fat reducing drugs.
    • Anti-diabetic or insulin sensitizing medications.
    • Systemic .
    • Systemic chemotherapy, interferon or radiation therapy treatment.
    • Androgenic agents including, but not limited to, testosterone, nandrolone (Deca-durabolin), oxandrolone (Oxandrin), oxymetholone (Anadrol), dehydroepiandrosterone (DHEA), etc. (Testosterone replacement therapy for hypogonadism is the exception to this exclusion and will be allowed if started >30 days prior to Study Day 1 of Serono Study 24380).
    • Progestational agents, unless used for oral or hormone replacement therapy.
    • Appetite stimulants such as dronabinol (Marinol), megestrol acetate (Megace), or cyproheptadine (Periactin).
    • agents, unless approved in advance by Serono's Medical Director. Specifically, experimental antiretroviral agents are disallowed, unless available under a treatment IND or expanded access program (30 days).
    • Liposuction or other elective plastic surgery.
    • Acquired Immune Deficiency Syndrome (AIDS) wasting therapy with growth hormone and/or prior treatment with growth hormone or a growth hormone releasing factor (for 12 months prior to the screening visit).
  • Are participating in any other clinical studies (except Serono Study 24380). Observation studies are allowed, but prior written permission by Serono Medical/Therapeutic Director must be granted.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
126 participants (actual)

Study arms

  • Experimental
    Serostim

    Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)

    Biological: Serostim

Interventions

  • BiologicalSerostim

    Serostim® 4 mg daily given for 12 weeks (following a prior 36-week treatment \[Serono Study 24380\] with Serostim® 4 mg daily given for 12 weeks, followed by 24-weeks of either Serostim® 2 mg every other day or Placebo every other day)

    Also known as: mammalian cell-derived recombinant human growth hormone, r hGH

06

What researchers measure

Primary outcomes

  1. Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan

    Time frame: baseline to 12 weeks

Secondary outcomes

  1. Change From Baseline to Week 12 in Waist Circumference

    Measured by anthropometry

    Time frame: baseline to 12 weeks

  2. Change From Baseline to Week 12 in Insulin-like Growth Factor I

    Circulating levels of IGF-I

    Time frame: baseline to 12 weeks

  3. Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin

    Oral glucose tolerance testing

    Time frame: baseline to 12 weeks

  4. Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose

    Oral glucose testing

    Time frame: baseline to 12 weeks

  5. Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose

    Oral glucose testing

    Time frame: baseline to 12 weeks

07

Results

Posted Jun 23, 2010

Participant flow

Study Initiation Date: 03 Feb 2005 (date of first subject, first dose) Study Completion Date 04 Jan 2006 (date of last subject, last visit) 26 study centers in the United States and British Columbia participated in this study, with each center enrolling at least one subject into the study.

Participant flow — Overall Study
MilestoneSerostim
Started126
Completed110
Not completed16
Withdrew: Adverse event6
Withdrew: Protocol violation3
Withdrew: Lost to follow-up5
Withdrew: Subject decision1
Withdrew: Reason unspecified1

Outcome measures

PrimaryChange From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan
Time frame:
baseline to 12 weeks
Reported as:
Mean · kg
Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan
kgSerostim
Change From Baseline to Week 12 in Trunk Fat as Assessed by Dual-Energy X-Ray Absorptiometry (DXA) Scan-1.7 ± 1.4
Statistical analysis
  • Serostim · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline to Week 12 in Waist Circumference

Measured by anthropometry

Time frame:
baseline to 12 weeks
Reported as:
Mean · cm
Change From Baseline to Week 12 in Waist Circumference
cmSerostim
Change From Baseline to Week 12 in Waist Circumference-1.5 ± 3.0
Statistical analysis
  • Serostim · t-test, 2 sided · p = <0.001
SecondaryChange From Baseline to Week 12 in Insulin-like Growth Factor I

Circulating levels of IGF-I

Time frame:
baseline to 12 weeks
Reported as:
Mean · ng/mL
Change From Baseline to Week 12 in Insulin-like Growth Factor I
ng/mLSerostim
Change From Baseline to Week 12 in Insulin-like Growth Factor I135.7 ± 210.7
Statistical analysis
  • Serostim · t-test, 2 sided · p = <0.001
SecondaryOral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin

Oral glucose tolerance testing

Time frame:
baseline to 12 weeks
Reported as:
Mean · mcIU/mL
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin
mcIU/mLSerostim
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Insulin10.8 ± 22.3
Statistical analysis
  • Serostim · t-test, 2 sided · p = <0.001
SecondaryOral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose

Oral glucose testing

Time frame:
baseline to 12 weeks
Reported as:
Mean · mg/dL
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose
mg/dLSerostim
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in 120 Minute Glucose11.7 ± 43.7
Statistical analysis
  • Serostim · t-test, 2 sided · p = 0.007
SecondaryOral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose

Oral glucose testing

Time frame:
baseline to 12 weeks
Reported as:
Mean · mg/dL
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose
mg/dLSerostim
Oral Glucose Tolerance Testing - Change From Baseline to Week 12 in Fasting Glucose4.5 ± 20.4
Statistical analysis
  • Serostim · t-test, 2 sided · p = 0.015

Adverse events

Collected over Adverse events were to be reported and collected on an ongoing basis from the day of written informed consent (baseline) until 4 weeks after the last investigational product administration.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Serostim—2/126 (1.6%)89/126 (70.6%)
Most frequent serious events
Most frequent serious events
EventSerostim
Cardiac failure congestiveCardiac disorders1/126
DiverticulitisInfections and infestations1/126
Most frequent other events
Most frequent other events
EventSerostim
Oedema peripheralGeneral disorders31/126
ArthralgiaMusculoskeletal and connective tissue disorders21/126
HypoaesthesiaNervous system disorders9/126
Blood glucose increasedInvestigations8/126
Joint swellingMusculoskeletal and connective tissue disorders8/126
MyalgiaMusculoskeletal and connective tissue disorders8/126
Pain in extremityMusculoskeletal and connective tissue disorders8/126
HyperglycaemiaMetabolism and nutrition disorders7/126
InsomniaPsychiatric disorders7/126
Musculoskeletal stiffnessMusculoskeletal and connective tissue disorders7/126

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Serostim
<=18 years0
Between 18 and 65 years126
>=65 years0
Age Continuous
Age Continuous(years)Serostim
Mean45.4 ± 7.1
Sex: Female, Male
Sex: Female, Male(Participants)Serostim
Female13
Male113
Region of Enrollment
Region of Enrollment(participants)Serostim
United States125
Canada1
Insulin-like Growth Factor I
Insulin-like Growth Factor I(ng/mL)Serostim
Mean242.6 ± 132.8
Oral Glucose Tolerance Testing - 120 Minute Glucose
Oral Glucose Tolerance Testing - 120 Minute Glucose(mg/dL)Serostim
Mean102.3 ± 35.7
Oral Glucose Tolerance Testing - Fasting Glucose
Oral Glucose Tolerance Testing - Fasting Glucose(mg/dL)Serostim
Mean94.5 ± 14.7
Oral Glucose Tolerance Testing - Fasting Insulin
Oral Glucose Tolerance Testing - Fasting Insulin(mcIU/mL)Serostim
Mean11.4 ± 13.6

2 further baseline measures are reported on the registry.

08

Study locations

26 sites
  • University of Alabama/Birmingham
    Birmingham, Alabama, United States
  • Care Clinic
    Los Angeles, California, United States
  • Private Practice
    Palm Beach, California, United States
  • UCSD - AVRC (AntiViralResearchCenter)
    San Diego, California, United States
  • Kaiser Permanente
    San Francisco, California, United States
  • Harbor-UCLA Medical Center
    Torrence, California, United States
  • AIDS Alliance
    West Hollywood, California, United States
  • Circle Medical LLC
    Norwalk, Connecticut, United States
  • Private Practice
    Washington, District of Columbia, United States
  • Private Practice
    Fort Lauderdale, Florida, United States
  • Care Resources
    Miami, Florida, United States
  • Private Practice
    Miami, Florida, United States
  • Private Practice
    North Miami Beach, Florida, United States
  • Infectious Disease Associates
    Sarasota, Florida, United States
  • AIDS Research Consortium of Atlanta
    Atlanta, Georgia, United States
  • Rush University Medical Center
    Chicago, Illinois, United States
  • Community Research Initiative of New England
    Boston, Massachusetts, United States
  • Tufts University School of Medicine
    Boston, Massachusetts, United States
  • Hennepin County Medical Center
    Minneapolis, Minnesota, United States
  • St. Luke's Roosevelt Hospital
    New York, New York, United States
  • St. Vincents Catholic Medical Center
    New York, New York, United States
  • Weill Medical College of Cornell University
    New York, New York, United States
  • Central Texas Clinical Research
    Austin, Texas, United States
  • IPD Research
    Annandale, Virginia, United States
  • Private Practice
    Spokane, Washington, United States
  • St Paul Hospital
    Vancouver, British Columbia, Canada
09

References and documents

Publications

  • Grunfeld C, Thompson M, Brown SJ, Richmond G, Lee D, Muurahainen N, Kotler DP; Study 24380 Investigators Group. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. J Acquir Immune Defic Syndr. 2007 Jul 1;45(3):286-97. doi: 10.1097/QAI.0b013e3180691145. PubMed 17592343 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2005, a primary completion of Jan 2006 and a completion of Jan 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Jun 2010, 4 years 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2010
First posted
Mar 1, 2010
Start
Feb 2005
Primary completionActual
Jan 2006
CompletionActual
Jan 2006
Results first posted
Jun 23, 2010
Last update
Aug 7, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01077960
Lead sponsor
EMD Serono
Responsible party
Sponsor
First posted
Mar 1, 2010
Start date
Feb 2005
Primary completion
Jan 2006
Completion
Jan 2006
Results posted
Jun 23, 2010
Last update
Aug 7, 2013

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Human Growth Hormone

Start the discussion